Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Liabilities (2016 - 2025)

Zevra Therapeutics' Total Liabilities history spans 11 years, with the latest figure at $130.1 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 6.06% year-over-year to $130.1 million; the TTM value through Dec 2025 reached $130.1 million, down 6.06%, while the annual FY2025 figure was $130.1 million, 6.06% down from the prior year.
  • Total Liabilities reached $130.1 million in Q4 2025 per ZVRA's latest filing, down from $137.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $139.0 million in Q2 2025 to a low of $4.2 million in Q1 2022.
  • Average Total Liabilities over 5 years is $65.9 million, with a median of $43.4 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: tumbled 92.59% in 2021, then skyrocketed 1947.43% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $5.8 million in 2021, then soared by 590.71% to $40.2 million in 2022, then surged by 174.65% to $110.5 million in 2023, then increased by 25.35% to $138.5 million in 2024, then decreased by 6.06% to $130.1 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Total Liabilities are $130.1 million (Q4 2025), $137.0 million (Q3 2025), and $139.0 million (Q2 2025).